BTIG raised the firm’s price target on Globus Medical (GMED) to $91 from $87 and keeps a Buy rating on the shares as part of a broader research note previewing 2025 in Medical Technology. The sector has now underperformed the S&P for four years in a row despite what we view as a return to healthy fundamentals in 2024, including strong procedure demand, healthy capital equipment trends, and a stable U.S. economy as a backdrop, the analyst tells investors in a research note. Globus Medical is the firm’s top pick in the sector, with BTIG noting that against the backdrop of the healthiest spine market in years, the company has opportunities for above market performance through new products and continued share gains.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMED:
- Globus Medical price target raised to $92 from $85 at Canaccord
- Globus Medical assumed at Overweight from Equal Weight at Morgan Stanley
- Globus Medical launches ExcelsiusHub navigation system
- Globus Medical price target raised to $83 from $74 at Morgan Stanley
- Globus Medical price target raised to $92 from $80 at Stifel